This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zbinden, R.
Right arrow Articles by von Graevenitz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zbinden, R.
Right arrow Articles by von Graevenitz, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 871-874, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.872-875.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of BAL9141, a Novel Broad-Spectrum Pyrrolidinone Cephalosporin, against Gram-Negative Nonfermenters

R. Zbinden,* V. Pünter, and A. von Graevenitz

Department of Medical Microbiology, University of Zurich, 8028 Zurich, Switzerland

Received 8 June 2001/ Returned for modification 18 October 2001/ Accepted 21 November 2001

The activities of BAL9141 (formerly Ro 63-9141), a novel pyrrolidinone-3-ylidenemethyl cephalosporin, against 244 strains of gram-negative nonfermenters were evaluated. The overall MIC at which 50% of isolates are inhibited (MIC50) and the overall MIC90 were 2 and 64 µg/ml, respectively, which are similar to those of imipenem, lower than those of the other cephalosporins tested, amoxicillin, and the ticarcillin-clavulanic acid combination, and much higher than those of ciprofloxacin. BAL9141 shows species-dependent activity in vitro against a variety of gram-negative nonfermentative pathogens.

* Corresponding author. Mailing address: Department of Medical Microbiology, University of Zurich, Gloriastrasse 32, 8028 Zurich, Switzerland. Phone: 41 1 634 27 00. Fax: 41 1 634 49 06. E-mail: RZbinden{at}immv.unizh.ch.

Antimicrobial Agents and Chemotherapy, March 2002, p. 871-874, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.872-875.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lemaire, S., Glupczynski, Y., Duval, V., Joris, B., Tulkens, P. M., Van Bambeke, F. (2009). Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1 Macrophages and Keratinocytes) Forms of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 2289-2297 [Abstract] [Full Text]  
  • Anderson, S. D, Gums, J. G (2008). Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin. The Annals of Pharmacotherapy 42: 806-816 [Abstract] [Full Text]  
  • Queenan, A. M., Shang, W., Kania, M., Page, M. G. P., Bush, K. (2007). Interactions of Ceftobiprole with {beta}-Lactamases from Molecular Classes A to D. Antimicrob. Agents Chemother. 51: 3089-3095 [Abstract] [Full Text]  
  • Lodise, T. P. Jr., Pypstra, R., Kahn, J. B., Murthy, B. P., Kimko, H. C., Bush, K., Noel, G. J., Drusano, G. L. (2007). Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects. Antimicrob. Agents Chemother. 51: 2378-2387 [Abstract] [Full Text]  
  • Davies, T. A., Page, M. G. P., Shang, W., Andrew, T., Kania, M., Bush, K. (2007). Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 2621-2624 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2006). In Vitro Activity of Ceftobiprole against Aerobic and Anaerobic Strains Isolated from Diabetic Foot Infections. Antimicrob. Agents Chemother. 50: 3959-3962 [Abstract] [Full Text]  
  • Davies, T. A., Shang, W., Bush, K. (2006). Activities of Ceftobiprole and Other {beta}-Lactams against Streptococcus pneumoniae Clinical Isolates from the United States with Defined Substitutions in Penicillin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x.. Antimicrob. Agents Chemother. 50: 2530-2532 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»